{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:21:14Z","timestamp":1790364074381,"version":"4.1.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:00:00Z","timestamp":1419292800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0114733","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T21:05:31Z","timestamp":1419368731000},"page":"e114733","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Randomized, Placebo Controlled Pilot Trial of Botulinum Toxin for Paratonic Rigidity in People with Advanced Cognitive Impairment"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02212119","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Galit","family":"Kleiner-Fisman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikohl","family":"Moncrieffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triina","family":"Forbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Gryfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,23]]},"reference":[{"key":"ref1","first-page":"54","article-title":"Debilite mentale and debilite motrice associees","volume":"20","author":"E Dupre","year":"1910","journal-title":"Rev Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1017\/S1041610207006424","article-title":"Diagnosing paratonia in the demented elderly: reliability and validity of the Paratonia Assessment Instrument (PAI)","volume":"20","author":"JS Hobbelen","year":"2008","journal-title":"Int Psychogeriatr"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/archneur.1993.00540100024010","article-title":"The neurologic syndrome of severe Alzheimer\u2019s disease. Relationship to functional decline","volume":"50","author":"EH Franssen","year":"1993","journal-title":"Arch Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/089198879701000301","article-title":"Neuromotor changes in Alzheimer\u2019s disease: implications for patient care","volume":"10","author":"LE Souren","year":"1997","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2318-7-30","article-title":"Passive movement therapy in patients with moderate to severe paratonia; study protocol of a randomised clinical trial (ISRCTN43069940)","volume":"7","author":"JS Hobbelen","year":"2007","journal-title":"BMC Geriatr"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1126\/science.785600","article-title":"Botulinum toxin: mechanism of presynaptic blockade","volume":"193","author":"I Kao","year":"1976","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"CL Comella","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","article-title":"Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis","volume":"40","author":"P Greene","year":"1990","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"MF Lew","year":"1997","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"D Truong","year":"2005","journal-title":"Mov Disord"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa011892","article-title":"Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke","volume":"347","author":"A Brashear","year":"2002","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.apmr.2008.01.007","article-title":"Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients","volume":"89","author":"EP Elovic","year":"2008","journal-title":"Arch Phys Med Rehabil"},{"key":"ref13","unstructured":"ClinicalTrials.Gov. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/prsinfo.clinicaltrials.gov\/ElaborationsOnDefinitions.pdf\" xlink:type=\"simple\">http:\/\/prsinfo.clinicaltrials.gov\/ElaborationsOnDefinitions.pdf<\/ext-link>. Accessed 2014 November 17."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jnnp.69.2.217","article-title":"Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial","volume":"69","author":"BB Bhakta","year":"2000","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/jnnp.2008.159657","article-title":"Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study","volume":"80","author":"DM Simpson","year":"2009","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","article-title":"Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity","volume":"32","author":"P Kanovsky","year":"2009","journal-title":"Clinical neuropharmacology"},{"key":"ref17","unstructured":"Delagi EF, Perotto A, Iazzetti J, Morrison D (1980) Anatomic Guides for the Elecromyographer. Springfield, Illinois: Charles C. Thomas."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0269215507072772","article-title":"Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis","volume":"21","author":"M Giovannelli","year":"2007","journal-title":"Clin Rehabil"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1017\/S1041610211002468","article-title":"Passive movement therapy in severe paratonia: a multicenter randomized clinical trial","volume":"24","author":"JH Hobbelen","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"ref20","first-page":"30","article-title":"Can paratonia be measured reliably? Evaluation of the reliability of a visual analogue scale and the modified tonus sclae of Ashworth for measuring paratonia","volume":"102","author":"H Waardenberg","year":"1999","journal-title":"Nederlands Tijdschrift voor Fysiotherapie"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/PL00007848","article-title":"A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia","volume":"249","author":"M Naumann","year":"2002","journal-title":"J Neurol"},{"key":"ref22","unstructured":"Waltz C, Lenz E (1991) Measurement in Nursing Research. Philadelphia: F.A. Davis."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.JAM.0000043422.31640.F7","article-title":"Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale","volume":"4","author":"V Warden","year":"2003","journal-title":"J Am Med Dir Assoc"},{"key":"ref24","unstructured":"Rabe-Hesketh S, Skrondal A (2012) Multilevel and Longitudinal Modeling Using Stata (Third Edition). College Station, TX: Stata Press."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jamda.2012.03.005","article-title":"Can botulinum toxin decrease carer burden in long term care residents with upper limb spasticity? A randomized controlled study","volume":"13","author":"K Lam","year":"2012","journal-title":"J Am Med Dir Assoc"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/00002512-200623090-00001","article-title":"A review of the health-related quality of life and economic impact of Parkinson\u2019s disease","volume":"23","author":"CH Dowding","year":"2006","journal-title":"Drugs Aging"},{"key":"ref27","unstructured":"Smetanin P, Stiff D, Briante C, Adair CE, Ahmad S, <etal>et al<\/etal>.<bold>.<\/bold> (2011) The Life and Economic Impact of Major Mental Illnesses in Canada: 2011 to 2041. RiskAnalytica, on behalf of the Mental Health Commission of Canada. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.mentalhealthcommission.ca\" xlink:type=\"simple\">http:\/\/www.mentalhealthcommission.ca<\/ext-link>. Accessed 2014 January 1."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0114733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:38:33Z","timestamp":1589002713000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0114733"}},"subtitle":[],"editor":[{"given":"Terence J.","family":"Quinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,23]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0114733","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,23]]}}}